赛伦生物(688163) - 2024 Q4 - 年度业绩

Financial Performance - Total operating revenue for 2024 reached RMB 194.92 million, a year-on-year increase of 2.51%[3] - Operating profit was RMB 52.19 million, reflecting a growth of 13.50% compared to the previous year[3] - Net profit attributable to shareholders of the parent company was RMB 45.40 million, up 17.08% year-on-year[3] - The net profit after deducting non-recurring gains and losses was RMB 29.36 million, an increase of 22.30% from the previous year[3] - Basic earnings per share rose to RMB 0.42, representing a 16.67% increase[3] Assets and Equity - Total assets at the end of the reporting period were RMB 1,124.40 million, a decrease of 0.36% from the beginning of the period[6] - Shareholders' equity attributable to the parent company increased to RMB 1,096.61 million, up 0.99% from the beginning of the period[6] Business Operations - The company focused on its main business, leading to increased product sales and production, contributing to stable revenue growth[7] - R&D expenses decreased compared to the previous year due to a high base effect from last year[7] - The company fully provided for impairment losses on long-term equity investments, impacting net profit growth[8]